Menstrual blood transplantation for ischemic stroke: Therapeutic mechanisms and practical issues

Interventional Medicine and Applied Science

Volumn 4, Issue 2, 2012, Pages 59-68

  Rodrigues, Maria Carolina O ^a,b   Dmitriev, Dmitriy ^a   Rodrigues, Antonio ^a,b   Glover, Loren E ^a   Sanberg, Paul R ^a   Allickson, Julie G ^c   Kuzmin Nichols, Nicole ^d   Tajiri, Naoki ^a   Shinozuka, Kazutaka ^a   Garbuzova Davis, Svitlana ^a   Kaneko, Yuji ^a   Borlongan, Cesar V ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Cryo Cell International Inc   (United States)

^d Saneron CCEL Therapeutics Inc   (United States)

Author keywords

cell based therapy; endometrium derived stem cells; menstrual blood stem cells; penumbra area; restorative treatment; stroke

Indexed keywords

EID: 84865259912     PISSN: 20611617     EISSN: 20615094     Source Type: Journal    
DOI: 10.1556/IMAS.4.2012.2.1     Document Type: Review

References (109)

1. Xu J et al.: Deaths, fnal data for 2007. National Vital Statistics Reports 57, 1-134 (2010)
2. Centers for Disease Control and Prevention (CDC): Prevalence of disabilities and associated health conditions among adults, United States. M.M.W.R. Morb Mortal Wkly Rep 50, 120-125 (1999)
3. Asplund K, Stegmayr B, Peltonen M (1998): From the twentieth to the twenty-frst century: A public health perspective on stroke. In: Cerebrovascular Disease Pathophysiology, Diagnosis, and Management, eds Ginsberg MD, Bogousslavsky J, Blackwell Science, MA, USA
4. Alexandrov AV et al.: Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy, sonographic classifcation and short-term improvement. Circulation 103, 2897-2902 (2001)
5. Marler JR et al.: Early stroke treatment associated with better outcome, the NINDS rt-PA stroke study. Neurology 55, 1649-1655 (2000)
6. Rha JH, Saver JL: The impact of recanalization on ischemic stroke outcome? A meta-analysis. Stroke 38, 967-973 (2007)
7. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group: tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333, 1581-1587 (1995)
8. Hacke W et al.: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). J.A.M.A. 274, 1017-1025 (1995)
9. Kleindorfer D et al.: National US estimates of recombinant tissue plasminogen activator use, ICD-9 codes substantially underestimate. Stroke 39, 924-928 (2008)
10. Carpenter CR et al.: The Best Evidence in Emergency Medicine Investigator Group. Thrombolytic therapy for acute ischemic stroke beyond 3 hours. J Emerg Med 40, 82-92 (2011)
11. Cronin CA: Intravenous tissue plasminogen activator for stroke, a review of the ECASS III results in relation to prior clinical trials. J Emer Med 38, 99-105 (2010)
12. Hacke W et al.: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359, 1317-1329 (2008)
13. Chavez JC et al.: Pharmacologic interventions for stroke: looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch. Stroke 40, e558-e563 (2010)
14. Green RA et al.: Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol Sci 24, 402-408 (2003)
15. NINDS; The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group: Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. Stroke 31, 2912-2919 (2000)
16. Hess DC, Borlongan CV: Cell-based therapy in ischemic stroke. Expert Rev Neurother 8, 1193-1201 (2008)
17. Hill WD et al.: SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury. J Neuropathol Exp Neurol 63, 84-96 (2004)
18. Choi DW, Rothman SM: The role of gutamete neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 13, 171-182 (1990)
19. Ankarcrona M et al.: Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15, 961-973 (1995)
20. Besancon E et al.: Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol Sci 29, 268-277 (2008)
21. Amor S et al.: Infammation in neurodegenerative diseases. Immunology 129, 154-169 (2010)
22. Emsley CA et al.: Infammation in acute ischemic stroke and its relevance to stroke critical care. Neurocrit Care 9, 125-138 (2008)
23. Koenigsknecht J, Landreth G: Microglial phagocytosis of f-brillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci 24, 9838-9846 (2004)
24. Takano T et al.: Astrocytes and ischemic injury. Stroke 40 (Suppl. 3), S8-S12 (2009)
25. Faulkner JR et al.: Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 24, 2143-2155 (2004)
26. Kriz J: Infammation in ischemic brain injury, timing is important. Crit Rev Neurobiol 18, 145-157 (2006)
27. Zhao Y, Rempe DA: Targeting astrocytes for stroke therapy. Neurotherapeutic 7, 439-451 (2010)
28. Borlongan CV et al.: Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. Stroke 35, 2385-2389 (2004)
29. Felfy H et al.: Hematopoietic stem cell transplantation protects mice from lethal stroke. Exp Neurol 225, 284-293 (2010)
30. Keimpema E et al.: Early transient presence of implanted bone marrow stem cells reduces lesion size after cerebral ischaemia in adult rats. Neuropathol Appl Neurobiol 35, 89-102 (2009)
31. Schwarting S et al.: Hematopoietic stem cells reduce post-isch-emic infammation and ameliorate ischemic brain injury. Stroke 39, 2867-2875 (2008)
32. Wu J et al.: Intravenously administered bone marrow cells migrate to damaged brain tissue and improve neural function in ischemic rats. Cell Transplant 16, 993-1005 (2008)
33. Koh SH et al.: Implantation of human umbilical cord-derived mesenchymal stem cells as a neuroprotective therapy for isch-emic stroke in rats. Brain Res 229, 233-248 (2008)
34. Liu YP et al.: The potential of neural stem cells to repair stroke-induced brain damage. Acta Neuropathol 117, 469-480 (2009)
35. Borlongan CV et al.: Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats. Exp Neurol 149, 310-321 (1998)
36. Jin K et al.: Comparison of ischemia-directed migration of neural precursor cells after intrastriatal, intraventricular, or intravenous transplantation in the rat. Neurobiol Dis 18, 366-374 (2005)
37. Takagi Y et al.: Survival and differentiation of neural progenitor cells derived from embryonic cells and transplanted into isch-emic brain. J Neurosurg 103, 304-310 (2004)
38. Taguchi A et al.: Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 114, 330-338 (2004)
39. Saghatelyan A: Role of blood vessels in the neuronal migration. Semin Cell Dev Biol 20, 744-750 (2009)
40. Fan Y et al.: Endothelial progenitor cell transplantation improves long-term stroke outcome in mice. Ann Neurol 67, 488-497 (2010)
41. Nakagomi N et al.: Endothelial cells support survival, proliferation, and neuronal differentiation of transplanted adult ischemia-induced neural stem/progenitor cells after cerebral infarction. Stem Cells 9, 2185-2195 (2009)
42. Barzilay R et al.: Adult stem cells for neuronal repair. Isr Med Assoc J 8, 61-66 (2006)
43. Hefti F: Pharmacology of neurotrophic factors. Annu Rev Pharmacol Toxicol 37, 239-267 (1997)
44. Loughlin AJ et al.: Modulation of interferon-gamma-induced major histocompatibility complex class II and Fc receptor expression on isolated microglia by transforming growth factor-beta 1, interleukin-4, noradrenaline and glucocorticoids. Immunology 79, 125-130 (1993)
45. Connor B, Dragunow M: The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Rev 27, 1-39 (1998)
46. Connolly ES Jr et al.: Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 97, 209-216 (1996)
47. Hurn PD et al.: T-and B-cell-defcient mice with experimental stroke have reduced lesion size and infammation. J Cereb Blood Flow Metab 27, 1798-1805 (2007)
48. Banwell S et al.: Systematic review and stratifed meta-analysis of the effcacy of interleukin-1 receptor antagonist in animal models of stroke. J Stroke Cerebrovasc Dis 18, 269-276 (2009)
49. Fan H et al.: Oxymatrine downregulates TLR4, TLR2, MyD88, and NF-kappaB and protects rat brains against focal ischemia. Mediators Infamm 2009, 704-706 (2009)
50. Wang X et al.: Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Mol Pharmacol 65, 890-896 (2004)
51. Yilmaz G, Granger DN: Leukocyte recruitment and ischemic brain injury. Neuromolecular Med 12, 193-204 (2010)
52. Enlimomab Acute Stroke Trial Investigators: Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 57, 1428-1434 (2001)
53. Faraji J et al.: Stress and corticosterone enhance cognitive recovery from hippocampal stroke in rats. Neurosci Lett 462, 248-252 (2009)
54. Linares G, Mayer SA: Hypothermia for the treatment of isch-emic and hemorrhagic stroke. Crit Care Med 37, S243-S249 (2009)
55. Matsukawa N et al.: Therapeutic targets and limits of minocy-cline neuroprotection in experimental ischemic stroke. B.M.C. Neurosci 10, 126 (2009)
56. Lee ST et al.: Anti-infammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke. Brain. 131, 616-629 (2008)
57. Kim SY et al.: Soluble mediators from human neural stem cells play a critical role in suppression of T-cell activation and proliferation. J Neurosci Res 87, 2264-2272 (2009)
58. Baraniak PR, McDevitt TC: Stem cell paracrine actions and tissue regeneration. Regen Med 5, 121-143 (2010)
59. Banerjee S et al.: Human stem cell therapy in ischaemic stroke: a review. Age Ageing 40, 7-13 (2011)
60. Park DH et al.: Infammation and stem cell migration to the injured brain in higher organisms. Stem Cells Dev 18, 693-701 (2009)
61. Le Belle JE et al.: Improving the survival of human CNS precursor-derived neurons after transplantation. J Neurosci Res 76, 174-183 (2004)
62. Fujiwara Y et al.: Intravenously injected neural progenitor cells of transgenic rats can migrate to the injured spinal cord and differentiate into neurons, astrocytes and oligodendrocytes. Neurosci Lett 366, 287-291 (2004)
63. Jablonska A et al.: Transplantation of neural stem cells derived from human cord blood to the brain of adult and neonatal rats. Acta Neurobiol Exp 70, 337-350 (2010)
64. Mitrecić D et al.: Distribution, differentiation, and survival of intravenously administered neural stem cells in a rat model of amy-otrophic lateral sclerosis. Cell Transplant 19, 537-548 (2010)
65. Sun L et al.: Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J Clin Invest 113, 1364-1374 (2004)
66. Park DH et al.: Human umbilical cord blood cell grafts for brain ischemia. Cell Transplant 18, 985-998 (2009)
67. Ourednik J et al.: Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat Biotechnol 20, 1103-1110 (2002)
68. Yasuhara T et al.: Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson's disease. J Neurosci 26, 12497-12511 (2006)
69. Daar AS et al.: Stem cell research and transplantation: science leading ethics. Transplant Proc 36, 2504-2506 (2004)
70. Umemura T et al.: Aging and hypertension are independent risk factors for reduced number of circulating endothelial progenitor cells. Am J Hypertens 21, 1203-1209 (2008)
71. Wagner W et al.: Aging and replicative senescence have related effects on human stem and progenitor cells. PLoS One 4, e5846 (2009)
72. Tan K et al.: Impaired function of circulating CD34(+) CD45(-) cells in patients with proliferative diabetic retinopa-thy. Exp Eye Res 91, 229-237 (2010)
73. Govaert JA et al.: Poor functional recovery after transplantation of diabetic bone marrow stem cells in ischemic myocardium. J Heart Lung Transplant 28, 1158-1165 (2009)
74. Antonucci I et al.: Amniotic fuid as rich source of mesenchy-mal cells for transplantation therapy. Cell Transplant Nov 5 [Epub ahead of print, doi:10.3727/096368910X53907] (2010)
75. Patel AN et al.: Multipotent menstrual blood stromal stem cells, isolation, characterization and differentiation. Cell Transplant 17, 303-311 (2008)
76. Yagi H et al.: Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant 19, 667-679 (2010)
77. Westrich J et al.: Factors affecting residence time of mesenchy-mal stromal cells (MSC) injected into the myocardium. Cell Transplant 19, 937-948 (2010)
78. Gerbal-Chaloin S et al.: Isolation and culture of adult human liver progenitor cells, in vitro differentiation to hepatocyte-like cells. Methods Mol Biol 640, 247-260 (2010)
79. Huang HI et al.: Multilineage differentiation potential of f-broblast-like stromal cells derived from human skin. Tissue Eng Part A 16, 1491-1501 (2010)
80. Mosna F et al.: Cell therapy for cardiac regeneration after myocardial infarct, which cell is the best? Cardiovasc Hematol Agents Med Chem 8, 227-243 (2010)
81. Prianishnikov VA: On the concept of stem cell and a model of functional-morphological structure of the endometrium. Contraception 18, 213-223 (1978)
82. Padykula HA: Regeneration in the primate uterus, the role of stem cells. Ann N Y Acad Sci 622, 47-52 (1991)
83. Chan RW et al.: Clonogenicity of human endometrial epithelial and stromal cells. Biol Reprod 70, 1738-1750 (2004)
84. Meng X et al.: Endometrial regenerative cells: a novel stem cell population. J Transl Med 5, 57 (2007)
85. Cervelló I et al.: Human endometrial side population cells exhibit genotypic, phenotypic and functional features of somatic stem cells. PLoS One 5, e10964 (2010)
86. Masuda H et al.: Human endometrial stem cells. PLoS One 5, e10387 (2010)
87. Murphy MP et al.: Allogeneic endometrial regenerative cells, an "off the shelf solution" for critical limb ischemia? J Transl 6, 45 (2008)
88. Taylor HS: Endometrial cells derived from donor stem cells in bone marrow transplant recipients. J.A.M.A. 292, 80-85 (2004)
89. Wolff EF et al.: Endometrial stem cell transplantation restores dopamine production in a Parkinson's disease model. J Cell Mol Med 15, 747-755 (2011)
90. Bratincsák A et al.: CD45-positive blood cells give rise to uterine epithelial cells in mice. Stem Cells 25, 2820-2826 (2007)
91. Hida N et al.: Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells 26, 1695-1704 (2008)
92. Drago H et al.: The next generation of burns treatment, intelligent flms and matrix, controlled enzymatic debridement, and adult stem cells. Transplant Proc 42, 345-349 (2010)
93. Borlongan CV et al.: Menstrual blood cells display stem celllike phenotypic markers and exert neuroprotection following transplantation in experimental stroke. Stem Cells Dev 19, 439-451 (2010)
94. Cho NH et al.: Lifetime expression of stem cell markers in the uterine endometrium. Fertil Steril 81, 403-407 (2004)
95. Zhong Z et al.: Feasibility investigation of allogeneic endome-trial regenerative cells. J Transl Med 7, 15 (2009)
96. Gargett CE et al.: Isolation and culture of epithelial progenitors and mesenchymal stem cells from human endometrium. Biol Reprod 80, 1136-1145 (2009)
97. Allickson JG et al.: Recent studies assessing the proliferative capability of a novel adult stem cell identifed in menstrual blood. Open Stem Cell J 3, 4-10 (2011)
98. Mazo M et al.: Transplantation of adipose derived stromal cells is associated with functional improvement in a rat model of chronic myocardial infarction. Eur J Heart Fail 10, 454-462 (2008)
99. Moon MH et al.: Human adipose tissue-derived mesenchymal stem cells improve postnatal neovascularization in a mouse model of hindlimb ischemia. Cell Physiol Biochem 17, 279-290 (2006)
100. Nakagami H et al.: Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol 25, 2542-2547 (2005)
101. Ikegame Y et al.: Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy. Cytotherapy 13, 675-685 (2011)
102. Kang SK et al.: Autologous adipose tissue-derived stromal cells for treatment of spinal cord injury. Stem Cells Dev 15, 583-594 (2006)
103. Ryu JK et al.: Neural progenitor cells attenuate infammatory reactivity and neuronal loss in an animal model of infamed AD brain. J Neuroinfammation 6, 39 (2009)
104. Xuqian W et al.: Intraocular transplantation of human adipose-derived mesenchymal stem cells in a rabbit model of experimental retinal holes. Ophthalmic Res 46, 199-207 (2011)
105. Poliachenko, Iu V et al.: Ultrastructural changes of vascular en-dothelium in patients with chronic ischemia of the extremities after conduction of multipotent stromal cells from adipose tissue transplantation. Klin Khir 6, 50-53 (2010)
106. Ra JC et al.: Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev (2011) [Epub ahead of print, doi: 10.1089/scd.2010.0466]
107. Kern S et al.: Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24, 1294-1301 (2006)
108. Zhang MJ et al.: Could cells from menstrual blood be a new source for cell-based therapies? Med Hypotheses 72, 252-254 (2009)
109. Cui CH et al.: Menstrual blood-derived cells confer human dystrophin expression in the murine model of Duchenne muscular dystrophy via cell fusion and myogenic transdifferentiation. Mol Biol Cell 18, 1586-1594 (2007)